July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Does low-dose atropine slow myopic eye elongation - Observations from humans?
Author Affiliations & Notes
  • Christine Frances Wildsoet
    UC Berkeley Myopia Research Group, Univ of California, Berkeley, Berkeley, California, United States
  • Footnotes
    Commercial Relationships   Christine Wildsoet, Nevakar (F)
  • Footnotes
    Support  NIH EY012392; Nevakar LLC (CHAMP study)
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 3295. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Christine Frances Wildsoet; Does low-dose atropine slow myopic eye elongation - Observations from humans?. Invest. Ophthalmol. Vis. Sci. 2019;60(9):3295.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Presentation Description : The problem of significant, unacceptable ocular side-effects associated with the use of daily 1% topical ophthalmic atropine presents a substantial obstacle to its wide-spread adoption, despite reports of robust inhibitory effects on myopia progression in children. However, recent reports of slowed myopia progression with much lower concentrations, with fewer associated side-effects, has lead to a rapid increase in the use of daily topical 0.01% atropine off-label around the world. This presentation will consider the pharmacological rationale for this treatment strategy and against this background, review the evidence that it slows eye elongation (as opposed to reducing myopic refractions), the variability in its effect, its dose-dependence and potential sites of action, based on related clinical studies.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.